ViroPharma's maribavir fails pivotal trial in bone marrow transplant
This article was originally published in Scrip
Executive Summary
ViroPharma's oral antiviral maribavir has failed to meet its primary endpoint in a Phase III trial in the prophylaxis of cytomegalovirus (CMV) disease in allogeneic stem cell (bone marrow) transplant patients, causing the company's share price to plummet 52% to close at $6.40 on February 9th on Nasdaq.